hsa-miR-155

ncRNA information

ncRNA name

hsa-miR-155

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

CD47/TNFAIP8

Cancer information

Cancer name

Multiple Myeloma

Cancer site

Multiple Myeloma

Treatment information

Treatment type

Chemotherapy

Drug

Bortezomib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-155 overexpression also re-sensitized drugresistant myeloma cells to bortezomib leading to cell death through targeting TNFAIP8.

Tissue resource

multiple myeloma pathologic specimens

multidrug-resistant multiple myeloma cell lines RPMI-8226-R5

multiple myeloma cell lines RPMI-8226

multiple myeloma cell lines MM.1S

multiple myeloma cell lines MM.1R

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

University of Toronto

H.Lee Moffitt Cancer Center and Research Institute

Country

Canada

USA

Continent

North American

North American